Role of PPARs (experimental paper) by Prof. F. Tacke

Prof. Frank Tacke discusses a paper in press in the Journal of Hepatology regarding the role of PPAR’s in experimental models and how these PPAR’s affect the progression of liver disease.
Play Video

We have an interesting experimental paper in press at the moment at the Journal of Hepatology. Analyzing the role of different selective PPAR agonists in experimental models of steatohepatitis and liver diseases. In this paper, we are able to show that the different isoforms of people which are transcription factors present in different cell types actually jointly affect the progression of liver diseases if stimulated, so if we treat mice in different models of non-alcoholic fatty liver disease and NASH (non-alcoholic steatohepatitis), we are able to demonstrate that stimulating several PPARS forms at the same time by a pan PPAR Agonist called lanifibranor is more effective than the selective stimulation and actually combines positive beneficial metabolic effects and anti-fibrotic. Of the selective pragmus this paper is impressive at the moment at the Journal of Hepatology, and I’m looking forward to its publication.

Prof. Frank Tacke

Prof. Frank Tacke

Frank Tacke was originally educated at the medical school in Hannover, Germany, and Baylor College of Medicine, Houston, TX. Later he stayed at University of Texas, M.D. Anderson Cancer Center in Houston, working on new gene therapy strategies (1998-1999) as well as for a post-doctoral research training (2004-2006) at the Mount Sinai Medical Center, New York, working on monocyte/macrophage and dendritic cell biology. Since 2006, he is a clinical physician and leader of a research laboratory at the University Hospital Aachen, Germany.

Video SERIES

SUBSCRIBE & FOLLOW US

Subscribe Our Newsletter To Get the Lastest Updates